Resumo: Safrol (1) obtido de óleos essenciais de diferentes espécies vegetais tem ampla aplicação na indústria química como precursor sintético do butóxido de piperonila, piperonal e de fármacos como a tadalafila, cinoxacina e levodopa. Do ponto vista toxicológico, é considerado uma hepatotoxina por mecanismo de bioativação metabólica conduzindo a formação de intermediários eletrofílicos, e tem sido descrito como inibidor de diferentes isoenzimas da família CYP450. A versatilidade de sua estrutura, permitindo várias transformações químicas, e a natureza biofórica de sua unidade benzodioxola ou metilenodioxifenila conferem-lhe características singulares, que o tornam atrativo material de partida para a síntese de compostos com distintas atividades farmacológicas. Exemplos selecionados de compostos bioativos, naturais e sintéticos, contendo o sistema benzodioxola serão comentados, incluindo aqueles provenientes de contribuição específica do LASSBio®.
1 U til 's Brazil as the ajor e porter of sassafras oil in the world, nowadays China and Vietnam are the great producers. The Ocotea pretiosa, a native tree in Mata Atlantica, typical from tropical rainforests, was the main store of the Brazilian sassafras oil until the depletion of this natural resource, placing it on the endangered list. Several others Lauraceae trees, which wood distillation was performed to yield a rich source of sassafras oil containing high amount of safrole, are also at risk of extinction.
Yunker in 1972, 1 Piper hispidinervium (known as long pepper) is a safrole-rich plant well distributed throughout South America and endemic in the state of Acre in Brazil. Its unique conditions for cultivation in areas with facilities for harvest, associated with high levels of safrole in its leaves, make the sustainable management and its economic exploration feasible. Others Piper species, including P. divaricatum P. nigrum, P. callosum and P. aduncum are also considered eventual sustainable source of safrole. 4, 5 Historically, the demand for sassafras oil depends mainly on the international market for piperonyl butoxide (PBO, 2), a semisynthetic derivative of safrole, that is a crucial component in the natural pyrethroid insecticides, due its synergist activity, and for heliotropin (3), used in flagrances and as flavoring agent (Figure 1) . 4, 5 The finding that heliotropin or piperonal (3), easily synthesized from safrole [6] [7] [8] ( Figure  2) , was a key intermediate in the synthesis of complex organic molecules expanded its value and its industrial application. In fact, 3 can be used as starting material from the synthesis of several biological active compounds, including the drugs cinoxacin (5), tadalafil (6) and levodopa (7) (Figure 2 ). It is also used in the synthesis of illicit drug 3,4-methylenedioxy-N-methylamphetamine (MDMA, ecstasy, 8). 
Toxicity and metabolism
The most important dietary sources of safrole (1) are nutmeg, mace and its essential oils, although it is also a natural constituent of cinnamon, anise, black pepper and sweet basil and is present in cola drinks.
9,10 Safrole (1) was first recognized to be a hepato ar i oge i the 's a d a animal studies have been documented concerning this toxicology. [11] [12] [13] [14] [15] Se eral atte pts to e plai safrole's muta-and genotoxicity have been made. In general, all hypotheses predict its bioactivation to produce electrophilic intermediates that are able to interact with DNA. [14] [15] [16] [17] [18] This bioactivation process is dependent of previous oxidative reactions catalyzed by different isoenzymes of cytochrome P450 (CYP450) family (Figure 3 ). In the first hypothesis, the allyl double bond of safrole (1) is oxidized to epoxide metabolite (9) , which can alkylate DNA (10) . This hypothesis is considered less likely, since metabolite 9 is fast hydrolyzed by microsomal epoxide hydrolase.
14, 16 The most well-established hypothesis is based on the rea ti it of eth le e C ' , oth all lic and benzylic, presented in the alkyl side chain of safrole (1) . 14, 17 This position is easily oxidized to '-hydroxy derivative (11) , by a classical CYP450 mediated hydroxylation. This metabolite (11) undergoes phase-2 metabolism by sulfotransferase (SULT), that catalyze the transfer of a sulfonate group (-SO − fro the ofa tor ′-phosphoadenosine-′-phosphosulfate (PAPS) to the hydroxyl group of 11, to furnish the metabolite 12 (Figure 3 cinoxacin (5) classical SN 2 reaction, eliminating sulfate ion (SO − ) and forming a covalent adduct of this essential macromolecule (13). An alternative mechanism is also possible and provides the loss of O-sulphate, resulting in a stabilized carbonium ion that form adducts with DNA and may be assumed to play a role in tumorigenesis. [19] [20] [21] [22] The third hypothesis is based on the bioactivation of safrole (1) by Odealkylation step of methylenedioxy subunity. The O-dealkylation process, catalyzed by CYP450 enzymes and which mechanism was elucidated by Fukuto and coworkers (1991) , 23 furnish the catechol metabolite (14). This metabolite can undergoes oxidation of 1 or 2 electrons to provide the ortho-semiquinone (15) or orthoquinone (16), respectively, generating reactive oxygen species that can promote oxidative DNA damage (Figure 3 ). The quinones are electrophiles as well as redoxactive compounds and, therefore, have been implicated as the ultimate cytotoxins formed from the oxidative metabolism of numerous aromatic compounds. 24 The o-quinone (16) undergoes nonenzimatic isomeration in order to produce the tautomer 17. This highly electrophilic p-quinone-methyde (17) is able to form covalent bond with bionucleophiles and consequently is able to alkylate the DNA. 
Role of cytochrome P450
Besides the central role of CYP450 in the bioactivation of safrole (1) (Figure 4 ). They also demonstrated that methylenedioxy bridge formation, in these conditions, was blocked by various CYP450 inhibitors, characterizing a cytochrome P450-dependent process.
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CYP450 enzymes have been shown to play essential roles in plant secondary metabolism, 29 and all members of the CYP719A subfamily, that have been characterized so far, catalyze methylenedioxy bridge formation in isoquinoline alkaloid biosynthesis. 30 As exemplified in Figure 5 , (S)-scoulerine (23) are converted at (S)-cheilanthiofoline (24) and (S)-stylopine (25) by methylenedioxy bridge formation from hydroxy-methoxyphenyl subunit catalyzed by CYP719A. Its conversion into berberine (29) requires oxidative cyclization catalyzed by berberine bridge enzyme (BBE) to furnish (S)-scoulerine (23), followed by its O-methylation to obtain (S)-tetrahydrocolumbamine (27) ( Figure 6 Compounds having 1,3-methylenedioxyphenyl or 1,3-benzodioxole subunit frequently elicit several different effects on CYP450-mediated pathways of drug oxidation in mammals and other species. It has been clearly established that these compounds inhibit the activity of CYP450 enzymes in a number of target species in vivo and in microsomal fractions in vitro. Considering that they also can be a substrate for CYP450 enzymes, is possible that this kind of inhibition may be due to a competitive mechanism. However, microsomal fractions incubated with piperonyl butoxide (PBO, 2) and NADPH showed decrease in CYP450 content, suggesting that the mechanism of inhibition was more complicated. Unusual Soret absorbances near 427 and 455 nm were detected in microsomal spectra during such incubations, proposing that 1,3-benzodioxole oxidation generate a metabolite-CYP450 complex that contribute to the observed decline in CYP450 content and in xenobiotic oxidation.
34,35
The nature of metabolite involved in the complexation of CYP450 and benzodioxole derivatives remains unclear. Several possible intermediates have been suggested. 36 Among then, formation of a carbene at the methylene carbon atom of methylenedioxy bridge receives most current support ( Figure  7) . [36] [37] [38] toward mexiletine p-hydroxylation in human liver microsomes, in a mechanism-based inactivation that seems to involve carbene-CYP450 complex (Figure 8 ). (36) within only a few hours of initial exposure to this metabolite ( Figure 9) . 40, 41 Despite the structure similarity with paroxetine (30) and their common metabolism pathway, the ability of zamifenacin (34) to inhibit CYP450 activity has not been studied. Safrole (1) is also a non-selective inhibitor of human CYP450, being able to inhibit the catalytic activity of CYP1A2, CYP2E1, CYP2A6, CYP2D6 and CYP3A4. The in vitro effects of safrole (1) on human CYP450 enzymes (CYPs) were studied using Escherichia coli-expressed bicistronic human CYPs. The IC 50 values of safrole for CYPs isoenzymes were in the order CYP2E1 (1.7  0.8 M) < CYP1A2 (5.7  0.9 M) < CYP2A6 (12.0  0.5 M) < CYP3A4 (43.5  8.5 M) < CYP2D6 (110  12 M).
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CYP6D1, a CYP isoenzyme responsible for pyrethroid resistance in the Learn-PyR (LPR) strain of house fly, was demonstrated to be inhibited by several 1,3-benzodioxole derivatives, mainly by piperonyl butoxide (PBO, 2). As a consequence, in the LPR strain, PBO (2) can enhance the toxicity of the pyrethroid insecticide permethrin 130-fold, which could explain the insecticide synergist activity of this safrole derivative. (1) is the simplest natural 1,3-benzodioxole derivative and, as previously mentioned, can be found as constituent of essential oil from different plant species. However, as exemplified in Figure 10 , more complexes structures containing 1,3-benzodioxole system can also be also found and includes lignans, flavonoids, isoflavonoids, alkaloids, and so on. 44 Figure 10 . Examples of natural products containing 1,3-benzodioxole subunit Among compounds exemplified in Figure  10 , teniposide (39 is ote orth . It's a se isynthetic lignin derivative approved by FDA as antitumor drug. It acts by inhibiting topoisomerase II, therefore, preventing DNA synthesis and hence replication. In clinical it has been used in association to treat pediatric patients with poor prognosis of acute lymphocytic leukemia. 51 Combretastatin A-2 (49, Figure 11 ) is also an important example of natural benzodioxole derivative. This rare Z-stilbene family of plant biosynthetic products is a key antineoplastic and cancer vascular targeting isolated from the South African bush willow tree Combretum caffrum. Guineensine (50, Figure 12 ) is a natural benzodioxole-alkenyl-N-isobutylamide derivative isolated from Piper nigrum. As described by Nicolussia and coworkers (2014), 53 guineensine (50) is a new nanomolar inhibitor (EC 50 = 290 nM) of cellular uptake of the endocannabinoid anandamide, through a mechanism of action that does 't i ol e i hi itio of endocannabinoid degrading enzymes such as fatty acid amide hydrolase (FAAH) or monoacylglycerol lipase (MAGL). Despite its ability to induce cannabimimetic effects in BALB/c mice, such as catalepsy, hypothermia and analgesia activity, it is not able to interact with cannabinoid receptors or fatty acid binding protein 5 (FABP5), a major cytoplasmic AEA carrier, revealing an intriguing mechanism of action that should be better elucidated.
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Figure 12. Structure of the natural benzodioxole-alkenyl-N-isobutylamide guineensine (50) isolated from Piper nigrum
The new benzodioxole neolignan (+)-kunstlerone (51, Figure 13 ), isolated from Beilschmiedia kunstleri, was first described by Mollataghi and coworkers in 2011. 54 This compound showed similar radical scavenging ability than ascorbic acid, determined in DPPH radical assay. 
Synthetic bioactive compounds
The peculiar reactivity of safrole (1) permits the selective modification of each functional group that compose its structure, 59 making it an attractive raw material for the synthesis of several biological compounds.
From the medicinal chemist's point of view, the 1,3-benzodioxole is a versatile biophore, which can be recognized by different bioreceptors, through hydrogen bond and/or hydrophobic interaction. These features make 1,3-benzodioxole system a common molecular fragment or scaffold in the structure of various synthetic bioactive compounds, as exemplified by the following examples.
Searching for melanin-concentrating hormone receptor (MCHr) antagonists as a strategy for anti-obesity pharmacotherapy, Lynch and coworkers (2006) 60 Widely distributed in the body, receptors for endothelin (ET) are present in blood vessels, brain, choroid plexus and peripheral nerves.
Several endothelin receptor antagonists have been identified, which differ in their selectivity toward the ET A and ET B receptors. Sitaxentan (59, Figure 19 ), a sulfonamide class of selective ET A receptor antagonist, was approved for the treatment of pulmonary hypertension. This derivative, presenting the 1,3-benzodioxole scaffold, was voluntarily withdraw (by Pfizer in 2010) from all markets worldwide and all ongoing clinical trials were discontinued, based on fatal cases associated with hepatic injury promoted by the use of sitaxentan (59, Figure  19 ). This compound (59) was also described to be an inhibitor of CYP2C9, with drug-drug interaction with warfarin, and to be a weak inhibitor of CYP2C19 and CYP3A4. 64, 65 Since the activation of endothelin ET A receptors has been implicated in diabetesinduced reductions in peripheral neurovascularization and concomitant endoneurial hypoxia, the amidebenzodioxole derivative ABT-627 (60, Figure  19 ) was evaluated in the streptozotocininduced diabetic rat model of neuropathic pain. This selective ET A antagonist receptor showed significant antinociceptive effect, that was maintained following chronic administration of ABT-627 (60). The inactivity observed for the homologous analogue A-192621 (61, Figure 19 ), a selective ET B antagonist receptor, revealed the dependence of selective blockade of ET A receptors to attenuate the tactile allodynia in the streptozotocin-treated rat. Figure 20 ) is a novel antiepileptic drug produced by Biocodex (Gentilly, France). It has been used as cotherapy for treatment of epilepsy for many years and it has been granted orphan drug status in the European Union for the treatment of severe myoclonic epilepsy in infancy. This benzodioxole-allylic alcohol (62) increases GABAergic transmission, in experimental models, and inhibits CYP3A4, CYP1A2 and CYP2C19 in epileptic patients. In attempt to modify the natural Zstilbene benzodioxole derivative, combretastatin A-2 (49), Pettit and coworkers (2003) 71 proposed modifications on its structure. Among these modifications the replacement of hydroxyl group by an isosteric amine unit provided compound 66, which was able to inhibit tubulin polymerization by binding at the colchicine site and showed potent antiproliferative activity against different human tumor cell lines, such as MCF-7, NCI-H460 and DU145 (Figure 22) . c-Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, and tumorigenesis. Increased Src activity has been reported in many types of human cancer and there is evidence that c-Src kinase activity is an important component of the invasive phenotype in both early and advanced solid tumors. For these reasons, the discovery of new c-Src inhibitors seems to be an important strategy for the development of new anticancer therapy. 75 In this context, the benzodioxole anilinoquinazoline derivative AZD0530 (saracatinib, 74, Figure 26) Other interesting target to anticancer drug development seems to be heat shock protein 90 (Hsp90). This protein regulates diverse cellular functions and exerts marked effects on normal biology, disease and evolutionary processes. 78 An important aspect of Hsp90 as a cancer target is the differential effect of Hsp90 inhibitors on cancer cells. Therefore, a variety of inhibitors that target the N-terminal ATP-binding site of Hsp90, blocking essential ATPase activity, have been described. Among them, the benzodioxole derivative MPC-3100 (75, Figure 27 ) was described as a promising drug candidate, which has completed a phase I clinical evaluation in refractory, or recurrent, cancer patients. This purine-based Hsp90 inhibitor showed great cytotoxic activity, adequate pharmacokinetic profile and antitumor effect in a human cancer xenograft model with concomitant and robust Hsp70 mRNA induction, a pharmacodynamic marker of Hsp90 inhibition. reported a noble activity for a simple and toxic benzodioxole derivative, the methylenedioxy--nitrostyrene (78, Figure  29 ). This compound (78) inhibits NLRP3 inflammasome, a critical component of the innate immune system, which activation is induced by diverse stimuli associated with bacterial infection or tissue damage. Since, the inappropriate activation of NLRP3 inflammasome is involved in the pathogenesis of inherited and acquired inflammatory diseases, its inhibition is considered a promise target to develop new anti-inflammatory drugs. 82 The ability of compound 78 to inhibit NLRP3 is dependent of the nitrovinyl moiety and seems to be a consequence of covalent reaction between the thiol group of cysteines in target proteins and electrophilic carbon of nitrovinyl subunit. Other important target for de development of anti-inflammatory drug candidates is human leukocyte elastase (HLE). This enzyme is a serine protease found in polymorphonuclear leukocytes, implicated in the extracellular degradation of structural proteins such as elastin and collagen. Therefore, the HLE inhibition has been thought to be strategic to treat diseases such as emphysema and cystic fibrosis. L-694,458 (79, Figure 30 ) is a potent monocyclic betalactam inhibitor of HLE, presenting satisfactory pharmacokinetic profile in male Sprague-Dawley rats and rhesus monkeys. In both monkey and human liver microsomes L-694,458 (79) acted as an inhibitor of testosterone 6--hydroxylation, indicating its ability to inhibit CYP3A4. 
LASSBio's ontri ution
During the 1970s, 1980s and 1990s, a major therapeutic interest was attributed to modulation of chemical mediators from the arachidonic acid cascade. By an intricate pathway, arachidonic acid is metabolized in prostaglandins, thromboxane, prostacyclins, leukotrienes, lipoxins and hepoxilin A3, which are known as eicosanoids. This complex family of lipid mediators regulates a wide variety of physiological responses and pathological processes. 84 In the context of the research activities realized at laboratory of evaluation and synthesis of bioactive compounds (LASSBio, in Portuguese: Laboratório de Avaliação e Síntese de Substâncias Bioativas), emphasis was given to the involvement of a particular group of eicosanoids named prostanoids (i.e. prostaglandins, thromboxanes and prostacyclins) in inflammation, platelet aggregation and vascular homeostasis. Therefore, and considering the biophoric features of benzodioxole subunit, the abundance of sassafras oil and the versatility of safrole (1) for chemical modifications, this natural essential oil was thought to be a great starting material to synthesize new antiinflammatory and antithrombotic agents. 85 Some chronological examples will be discussed as follows.
The first Brazilian work describing the use of safrole (1) in the synthesis of potential anti-inflammatory lead-compound dates fro , t el e ears efore LASSBio's foundation. In a collaboration between professors Eliezer J Barreiro, from Federal University of São Carlos (UFSCar), and Paulo R. R. Costa, from Federal University of Rio de Janeiro (UFRJ), the indolylacetic acids 81 and 82 were synthetize in 6 and 9 linear steps, respectively, employing safrole (1) as starting material. 86 These acids were designed considering the ability of indolylacetic acid framework to conjugate the minimal structural requirements to modulate prostaglandins formation, through inhibition of cyclooxygenases, as observed for the prototype indomethacin (80). Therefore, indolylacetic acids 81 and 82 could be hypothetically considered simplified analogues of indomethacin ( Figure 31 ). In the context of the same scientific collaboration some prostaglandin and thromboxane analogues were synthesized from safrole. 87, 88 The benzodioxole derivative 84 was designed as structural analogue of prostaglandin E1 (PGE 1 , 83) , an important vasodilatory lipid mediator, preserving in this structure the pharmacophoric points for molecular target recognition (Figure 32) . 87 A thromboxane A 2 (TXA 2 , 85) analogue (86) was also synthesized in 6 linear steps from safrole ( Figure 33) . 88 A series of homologous of the  and  side-chains of TXA 2 was likewise prepared to furnish different analogues of compound 86, including derivative 87.
indomethacin (80)
H
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The conformational restriction approach was likewise employed on the structure of prostaglandin analogue 84, in order to design compound 88 that was synthesized in 8 linear steps from safrole ( Figure 34) . The papers published by Pereira and coworkers (1989) 91 and Barreiro and Lima (1992) 92 are emblematic landmarks. From the philosophical point of view they can be considered the embryos for LASSBio® (http://www.farmacia.ufrj.br/lassbio/) foundation in 1994. The first successful rapprochement between medicinal chemists and pharmacologists came through these works. From this scientific collaboration with Department of Basic and Clinical Pharmacology of UFRJ, a series of sulindac analogues synthesized from safrole (1) was evaluated in murine model of inflammation by oral administration. This series (91-92, Figure 35 ) was designed like a me-too drug of sulindac (89) , exploring the isosteric relationship between fluorophenyl group and benzodioxole system. The methyl homologous derivatives were also synthesized to furnish asymmetric propanoic acids 93 and 94 (Figure 35 ). Safrolac derivatives 92 and 94 were equipotent as analgesic, while compounds 91 and 93 demonstrated de best anti-inflammatory profile, although less potent than the standard sulindac (89) . (89) and synthesized from safrole (1) In similar manner, others me-too analogues of anti-inflammatory drugs were synthesized from safrole (1) (Figure 36 ). The safroxican 96 was designed as a retroisoster of piroxicam (95), where the phenyl group was replaced by a benzodioxole subunit and the 2-piridinyl nucleus by a phenyl ring, in a classical isosteric ring interchange.
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Safrodolac 98 was also prepared and designed by molecular simplification on structure of etodolac (97), followed by ring isosterism (Figure 36 ). This analogue (98) showed significant anti-inflammatory activity by oral administration in carrageenan paw edema assay.
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In an attempt to optimize the antiinflammatory activity of safrodolac (98), novel spiroisochromanyl acid derivatives (99 and 100) were synthesized in 4 linear steps from safrole (1). These compounds were designed as conformationally restricted analogues of safrodolac (98), by cyclization of pentanoic acid framework into a cyclopentanecarboxylic acid in 99 or into a cyclohexanecarboxylic acid in the homologous 100 ( Figure 37 ). These restricted analogues showed poor anti-inflammatory profile and a powerful analgesic activity by oral administration.
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Assuming that the conformational restriction could be responsible by the loss of anti-inflammatory activity observed for compounds 99 and 100, the benzodioxoleisochromanyl system was modified once more. In this context, safrodolac (98) was modified through functionalization of carboxylic acid into an N-acylhydrazone (Figure 38 ). Among the isochromanyl-Nacylhydrazones synthesized using safrole (1) as starting material, compound 101 standing out. This compound showed remarkable analgesic activity in acetic acid-induced abdominal constriction in mice, although it still presents unsatisfactory antiinflammatory activity in carrageenan-induced paw edema in rats. (1) The recognition of the existence of two cyclooxygenase (COX) or prostaglandinendoperoxide synthase (PGHS) isoforms prompted the search for selective COX inhibitors. The assumption that COX-1 was produced constitutively (i.e., gastric mucosa) whereas COX-2 was inducible (i.e., in sites of inflammation), indicated the possibility to modulate the formation of prostanoids related to inflammatory response, without interference with those related to homeostatic functions. Based on this statement, several COX-2 inhibitors were developed and some of them were introduced as second generation of nonsteroidal anti-inflammatory drugs, such as celecoxib and rofecoxib. 97 Aiming to discover a new COX-2 inhibitor, Lages and co-workers (1998) 98 described the design of safrolide 103, planned exploring the isosteric relationship between indanone ring of the prototype flosulide (102), a selective COX-2 inhibitor, and benzodioxole system; and the isosteric replacement of oxygen atom by a methylene group in compound 103 (Figure 39 ). This flosulide analogue (103) was synthesized in 6 linear steps from safrole (1) and showed antiinflammatory activity, by oral administration, in carrageenan-induced rat pleurisy and paw edema models. Benzodioxole-N-acylhydrazone derivatives with outstanding analgesic activity were also synthesized from safrole (1). Compound 104, designed by molecular simplification on the structure of prototype 101, showed similar analgesic activity than indomethacin in acidacetic induced constrictions in mice, while its linear C2 homologous 105, less conformationally restricted, showed superior analgesic activity than the standard indomethacin, by oral administration in screening dose of 100 Mol/kg (Figure 40) . (1) and designed by molecular simplification on prototype 101
Exploring the isosteric relationship between carbonyl and sulfonyl functions, a series of N-sulfonylhydrazones was designed and synthesized from safrole (1). Comparatively to the N-acylhydrazone 104, compound 106 was demonstrated to be less analgesic. 99 The further substitution of Ndimethylamine group by acidic one, such as CO 2 H (107) or OCH 2 CO 2 H (108) (Figure 41 ), resulted in increase of analgesic activity and satisfactory anti-inflammatory profile. Further modifications were also performed on structure of linear homologous prototype 105. These modifications were based on the isosteric replacement of divalent groups (CH 2 x O) and the introduction of a monovalent electron withdrawing group (i.e. NO 2 ) at carbon 6 of benzodioxole subunity, resulting in design conception of compounds 109 and 110 ( Figure 42 ). These compounds showed better analgesic activity than dypyrone, in screening dose of 100 Mol/kg (per os) in acid-acetic induced constrictions in mice model. The loss of analgesic activity found for compound 111, in same experimental conditions, indicated the pharmacophoric profile of orthonitrophenyl framework (Figure 31 ). (1) and designed by isosteric replacement on prototype 105
In order to improve the anti-inflammatory and analgesic profile of prototype 110, a new series of nitro-benzodioxole-N-acylhydrazone derivatives were proposed, by molecular hybridization between 110 and nimesulide (112), a selective COX-2 inhibitor, followed by elimination of oxa-alkyl (OCH 2 ) side chain (Figure 43 ). The idealized hydrid compound (113) led the design of compounds 114 and 115 by replacement of phenylsulfonylamine moiety by a diterbutilphenol and phenyl subunits, respectively (Figure 43) . In carrageenan-induced rat paw edema assay, compound 115 was inactive, while 114 showed significant anti-inflammatory activity. Curiously this compound (114) showed great antinociceptive activity in the first phase of formalin test and was inactive in the second phase, showing a pharmacological profile different from non-steroidal antiinflammatory drugs. These results indicated a central analgesic activity that was confirmed by the hot plate test in mice. Further studies were realized and characterized compound 114 as a non-selective cannabinoid ligand having also antioxidant properties. Benzodioxole derivatives with antiplatelet activity, planned as new antithrombotic drug candidates, were synthesized and designed in order to modulate de effects evoked by the prostanoid thromboxane A 2 (TXA 2 ). TXA 2 (79) is an unstable arachidonic acid metabolite that plays a key role in normal physiology and control of vascular tone and platelet aggregation. It is a vasoconstrictor and potent hypertensive agent, able to trigger platelet aggregation. It achieves its biological effect through interaction with specific receptors named thromboxane A 2 receptors (TP). Therefore, the design of TP antagonists has been proposed as potential therapeutic agent for thrombosis.
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Considering the structure of sulotroban (BM 13.177; 116), a selective TP receptor antagonist, and looking for new antithrombotic agents, a me-too derivative (117) was proposed by replacing the phenyl ring of 116 by the 1-methyl-4,5-benzodioxole subunit ( Figure 44 ). Compound 117, named safroloban, was able to inhibit platelet aggregation induced by a stable TXA 2 analogue (U-46619). However the low potency observed for safroloban (IC 50 = 329 M) indicated the detrimental role of the 1-methyl-4,5-benzodioxole moiety for the antiplatelet activity. 104 The simultaneous attempt to design a hydrid between safroloban (117) and SQ29,548 (118), a highly selective TP receptor antagonist, also resulted in compound with weak platelet antiaggregant activity (Figure 45 ). (1) Safrole (1) was also used as starting material for the synthesis of a new structural analogue of ridogrel (120), a dual thromboxane synthase inhibitor and receptor antagonist.
This analogue (121) was designed by the replacement of 3-pyridyl ring of 120 by a benzodioxole subunit, followed by cyclization of oxime side-chain, in order to obtain a conformationally restricted analogue ( Figure 46 ). Although safrodogrel (121) retains, in theory, all the pharmacophoric points to interact with the targets (TP receptor and thromboxane synthase), it was unable to inhibit platelet aggregation. This result can indicate that comparatively with ridogrel (120) compound 121 has the pharmacophoric points in inadequate geometry or conformation, preventing their recognition by the receptor sites. In the context of LASSBio´s research activities, safrole (1) was still employed in the synthesis of bioactive compounds not related to arachidonic acid cascade, and some examples will be presented.
Thrombin is a serine protease that plays a central role in thrombosis and hemostasis, not only by its ability to convert fibrinogen into fibrin, but also by direct stimulation of platelet aggregation. p38 Mitogen-activated protein kinase (p38 MAPK) is an important signal transducing enzyme involved in many cellular regulation process, pain and inflammation. p38 MAPK activation occurs in response to several extracellular stimuli such as UV light, heat, osmotic shock, inflammatory cytokines and growth factors. Its inhibition has been proposed as a therapeutic strategy to treat inflammatory disorders and neuropathic pain. Aiming to discover a new p38 MAPK inhibitor, compound 128 was designed by ring isosteric replacement of thiophene by quinoline, maintenance of urea pharmacophoric group and the ester subunit present in the prototype GK-00687 (127) (Figure 48 ). Further substitution of phenyl ring by a cyclohexyl unit resulted in the most promise derivative from the series (129). This compound (129, Figure 48) showed, by docking studies, favorable interactions with p38 MAPK, binding in the same region proposed for binding of GK-0068. It also presented great analgesic and antiinflammatory activities in antigen (mBSA)-induced arthritis and rat paw edema models, and was able to modulate TNF production and inhibited LPS-induced p38 MAPK phosphorylation in lung tissue and in isolated macrophages. Benign prostatic hyperplasia (BPH) is a progressive disease, characterized by a noncancerous enlargement of the prostate gland, resulting in symptoms such as frequent urination, urgency, nocturia, decreased and intermittent force of stream, and the sensation of incomplete bladder e pt i g. Se eral α 1 -adrenergic receptors antagonists can be used in the treatment of symptomatic BPH. A o g the α 1 -adrenergic re eptors, su t pe α 1A is the predominantly expressed in human prostate. In attempt to discover new drugs candidates to treat BPH a series of functionalized benzodioxole methylenepiperazine was designed, considering the pharmacophoric models proposed for α 1A antagonist. From this studies compound 133 (Figure 50 ) highlighted as a novel potent and selective α 1A/1D (Ki = 0.14 nM and 0.025 nM, respectively) antagonist, 120-fold more potent than BMYas α 1D antagonist.
Ki ( A ) = 0.14 nM Ki ( D = 0.025nM An emblematic example of benzodioxole derivative synthesized in LASSBio®, having an exceptional myriad of pharmacological activity, is compound 134, named LASSBio-294 (Figure 51 ). This benzodioxole-Nacylhydrazone derivative has inotropic and lusitropic activities; being able to decrease cardiac remodeling and to improve Ca 2+ Influx into sarcoplasmic reticulum after myocardial Infarction.
112 It is also able to increase inotropism and decreases fatigue of skeletal muscle. 113 The metabolism of this benzodioxole bioactive compound (134) was studied in vitro using recombinant cytochrome P450 (CYP450) enzymes and rat liver microsomes. CYP1A2 is the main isoenzyme involved in LASSBio-294 metabolism, which performed the oxidative cleavage of the methylenedioxy bridge, in a classical O-dealkylation step, to furnish the catechol metabolite 135 (Figure 51 ). 114 However, a different metabolite was identified in serum of dog treated orally with LASSBio-294. This metabolite (136) formed by oxidation of the sulfur atom of the thiophene ring, was also identified in metabolism studies using fungus Beauveria bassiana ATCC 7159 (Figure 51 ). 
Final remarks
Combining the chemical versatility and the biophoric features, safrole (1) can be considered an extraordinary raw material for the synthesis of several and distinct bioactive compounds. However, the proposed molecular reasons for safrole´s toxicity highlight the eminent toxicophoric profile of allylbenzyl subunit and the potential toxicophoric feature of benzodioxole framework.
Although benzodioxole is found in the structure of drugs like cinoxacin (5), tadalafil (6), paroxetine (30), teniposide (39), trabectedin (53) and stiripentol (62), the presence of this subunit in compounds of therapeutic interest anticipates the possibility of toxic effects or drug-drug interactions, through its ability to inhibit CYP450 isoenzymes. However, it is noteworthy that the toxicity of this subunit of safrole' stru ture a e o sidera l different when presented in the structure of more complex and functionalized molecules. Since the mechanism of action proposed for benzodioxole toxicity provides preliminary step of metabolic bioactivation, with cleavage of methylenedioxy bridge by a Odealkylation step to furnish the catechol metabolite, that would be oxidized into quinone or quinone-methyde, which are responsible for covalent binding to endogenous bionucleophiles. Nevertheless, is important to consider that the first step of this process will depend on the affinity of the molecule and not the affinity of the fragment (i.e. benzodioxole) by metabolic enzymes. On the other hand, the second step will depend on: the rate of catechol conjugation with phase II metabolic enzymes, its redox potential and the structural features (electronic and steric) of the eventual quinone metabolite. However, even for considered safety drugs, idiosyncratic responses to compounds containing this molecular fragment may occur and should not be overlooked. 
